Cahill Represents Financing Sources in Valeant and Biovail Merger

June 21, 2010

Cahill is representing the financing sources in connection with providing $2.8 billion of financing for the merger of specialty pharmaceuticals companies Valeant Pharmaceuticals International and Canada's Biovail Corp.